1. Ursodeoxycholic acid shows antineoplastic effects in bile duct cancer cells via apoptosis induction; p53 activation; and EGFR-ERK, COX-2, and PI3K-AKT pathway inhibition
   Jin Lee et al, 2021, Molecular Biology Reports CrossRef
2. Evaluation of the Anticancer Activity of a Bile Acid-Dihydroartemisinin Hybrid Ursodeoxycholic-Dihydroartemisinin in Hepatocellular Carcinoma Cells
   Tzu-En Huang et al, 2020, Frontiers in Pharmacology CrossRef
3. Bibliometric study on the utilization of sorafenib in hepatocellular carcinoma
   Wenjun Meng et al, 2024, Frontiers in Oncology CrossRef
4. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway
   Yang Zhang et al, 2022, Frontiers in Oncology CrossRef
5. Ursodeoxycholic Acid Platinum(IV) Conjugates as Antiproliferative and Antimetastatic Agents: Remodel the Tumor Microenvironment through Suppressing JAK2/STAT3 Signaling
   Yan Chen et al, 2024, Journal of Medicinal Chemistry CrossRef
6. Berbamine (BBM), a Natural STAT3 Inhibitor, Synergistically Enhances the Antigrowth and Proapoptotic Effects of Sorafenib on Hepatocellular Carcinoma Cells
   Weijia Zhao et al, 2020, ACS Omega CrossRef
7. The anticancer activity of bile acids in drug discovery and development
   Weijian Li et al, 2024, Frontiers in Pharmacology CrossRef
8. Anticarcinogenic effects of ursodeoxycholic acid in pancreatic adenocarcinoma cell models
   Patrik Kovács et al, 2024, Frontiers in Cell and Developmental Biology CrossRef